Tilak Healthcare Receives Positive Opinion in France for Early Reimbursement of Odysight Telemonitoring Device
Paris-based digital health company Tilak Healthcare has announced a major regulatory milestone: a positive opinion from the French National Health Authority (Haute Autorité de Santé, HAS) for the early reimbursement of its ophthalmology telemonitoring platform, Odysight. This decision was granted under the PECAN (Prise En Charge Anticipée des dispositifs médicaux Numériques) scheme, which facilitates early access to digital medical devices. The recognition is expected to significantly improve patient access to remote vision monitoring in France and potentially across Europe.
Regulatory Milestone Under the PECAN Scheme
The PECAN program is designed to fast-track innovative digital medical technologies that demonstrate strong clinical potential. HAS's favorable opinion for Odysight marks a critical step in integrating digital tools into routine ophthalmic care, allowing eligible patients to access reimbursed telemonitoring services earlier than through standard reimbursement channels.
CEO Statement
“This reimbursement of Odysight is a recognition of our vision and the culmination of years of collective work,” stated Edouard Gasser, co-founder and CEO of Tilak Healthcare. “We thank public authorities, our partners, physicians, and patients for their trust. We are thrilled to share our innovation more widely and make it accessible to as many patients as possible."
He added, "This recognition reinforces our position as the French and European leader in ophthalmology telemonitoring. We will now focus on expanding our scientific evidence base to demonstrate the clinical impact of our innovations, with the goal of becoming the global leader in at-home monitoring of visual disorders and strengthening new strategic alliances that create real value.”
About Odysight
Odysight is a CE-marked, prescription-only digital medical device designed for smartphones and tablets. It enables patients with chronic maculopathies, including age-related macular degeneration (AMD), to self-administer vision tests at home. These tests track visual acuity changes between clinical visits, with the results automatically transmitted to the treating ophthalmologist.
When a decline in vision is detected, the physician receives an immediate alert, enabling early clinical intervention and personalized treatment adjustments. This capability not only enhances patient follow-up but also strengthens the continuity of care.
